Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA,a 24-week,prospective, randomized,placebo-controlled pilot trial期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA,a 24-week,prospective, randomized,placebo-controlled pilot trial

Authors:	Jürgen Harreiter PhD Ivica Just PhD Michael Leutner PhD Magdalena Bastian BSc Helmut Brath MD Christian Schelkshorn MD Radka Klepochova PhD Martin Krššák PhD Alexandra Kautzky-Willer MD

Affiliation:	1. Gender Medicine Unit, Division of Endocrinology and Metabolism, Department of Medicine III, Medical University Vienna, Vienna, Austria;2. Department of Biomedical Imaging and Image-Guided Therapy, High-Field MR Center, Medical University of Vienna, Vienna, Austria Division of Endocrinology and Metabolism, Department of Medicine III, Medical University Vienna, Vienna, Austria;3. Diabetes Outpatient Clinic, Health Centre Favoriten, Vienna, Austria;4. Department of Medicine, State Hospital Stockerau, Stockerau, Austria

Abstract:

Keywords:	CVD ectopic lipids GLP-1 receptor agonist glycaemic control magnetic resonance imaging metabolic syndrome NAFLD obesity prevention SGLT2 inhibitor type 2 diabetes mellitus weight loss